April 7, 2026
john-wilkerson-avatar-teal
Washington Correspondent, D.C. Diagnosis Writer

The 2026 STAT Madness competition was stacked with research on topics like smart dental floss that monitors stress, Baby KJ’s personalized gene therapy, and an artificial intelligence model designed to predict cell behavior. Check out the winner, unveiled this morning. And as always, send news tips to John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal.

politics

Budget reruns

The 2027 budget that the Trump administration released on Friday is in many ways a repeat of last year’s proposal: It includes deep cuts to the National Institutes of Health, the elimination of a health research agency, and the creation of a new agency devoted to chronic diseases called the Administration for a Healthy America.

Trump’s plan would cut the NIH’s budget by $5 billion, according to Megan Molteni and Anil Oza, and the White House wants to eliminate institutes studying health disparities and alternative medicine.

Congress didn’t go along with those cuts last time and it’s not expected to do so now. What’s more, Congress is unlikely to fund the government before the upcoming midterm elections, and Republicans might not control both chambers next year.



fda

Budget news nuggets

There are lots of new policy ideas in the budget, including a couple proposed by the Food and Drug Administration that caught our eye. They’re aimed at encouraging domestic development and manufacturing of drugs.

The administration is worried about early drug development moving to China, where regulations are less strict and companies can start testing in humans faster. Foreign drug manufacturing also is a concern, and President Trump has used the threat of tariffs to get companies to invest in U.S. manufacturing.

The FDA budget justification proposes to make it easier to run early-stage trials in the U.S., which was praised by venture capitalists and biotech lobbyists, and to hand an advantage to domestic generics manufacturers. Read more from me and Lizzy Lawrence.


HHS

Three double-headers for RFK Jr.

Health secretary Robert F. Kennedy Jr. is scheduled to appear before six congressional committees, two each on three days, to discuss the president’s budget, according to Washington Post reporter Megan Wilson.

The hearings could be lively. Republicans rejected proposed cuts to NIH funding last year, and Senate Committee on Appropriations Chair Susan Collins (R-Maine) said again last week that she opposes cuts to biomedical research.

Kennedy also hasn’t been making the quarterly visits to the Senate health committee that Chair Sen. Bill Cassidy (R-La.) demanded in return for his vote to confirm the health secretary. It’s not clear whether Cassidy, who faces a difficult primary in a state where Trump is popular, will challenge the health secretary on vaccine policies.

The budget steers clear of vaccine policy, which is in line with the administration’s goal of downplaying policies unpopular with voters. However, Democrats could use the hearings as an opportunity to attack Kennedy on topics such as the measles outbreak.


research funding

He reinvented genetics education. Then he lost his job

Megan Molteni wrote an excellent story about Brian Donovan, a recipient of the Genetics Society of America’s prestigious Elizabeth W. Jones Award for Excellence in Education.

Donovan was described by one of his peers as a “generational talent.” After years of interdisciplinary research, he developed a new way to teach genetics in high school that reduces racism.

But when the Trump administration terminated Donovan’s National Science Foundation grants, he found himself unemployed. He’s now preparing to apply to nursing school. Some of the work he started will continue, but more slowly and at a much smaller scale.

There’s a lot to this sad tale. You should read all of it.


medicare advantage

Insurers score a win

Under pressure from industry, the Trump administration scrapped a new risk-adjustment model, Bob Herman writes. The final rule for 2027 Medicare Advantage payment rates will hike base pay 2.5% on average, which is significantly more than what was proposed.

All told, the finalized rule is estimated to add $13 billion in revenue next year for insurers.

Read more.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we’re reading

  • Pharma companies and patient groups seek to exempt orphan drugs from Colorado pricing limits, STAT
  • RFK Jr. launches midterm travel push to shore up ‘MAHA’ support, Politico
  • How a four-month FDA delay forced a small biotech company to close its doors, STAT
  • Trump’s obesity drug plan for Medicare would cost insurers billions, Bloomberg

Thanks for reading! More nex